Veraxa Biotech has entered a joint discovery partnership with OmniAb tp develop a bispecific antibody drug conjugate (bsADC) ...

VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, “Voyager”), announced today a co ...

Groundbreaking treatment enhances the immune system's ability to fight cancer Holy Cross Health now offers bispecific therapy ...

"Additionally, this dataset showed that there is exciting potential, in certain therapeutic settings, for augmenting our bispecific antibodies with a cytotoxic payload to drive even broader ...

The use of mimicking antibodies that activate death receptors (DRs) to selectively induce cell death in cancer cells has ...

After issues at a third-party manufacturer caused the FDA to reject Regeneron's multiple myeloma bispecific antibody ...

Programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF) are often co-expressed in the tumor microenvironment. The combination of anti-PD-1 and anti-VEGF agents has been ...

We are proud to showcase a batch of preclinical research findings at this year's AACR Annual Meeting, including multiple globally first-in-class bispecific antibodies, multi-specific antibodies, and ...

Under the terms of the agreement, VERAXA will initiate a novel bispecific antibody drug conjugate ... changes to the proposed structure of the Business Combination that may be required or ...

We are proud to showcase a batch of preclinical research findings at this year's AACR Annual Meeting, including multiple globally first-in-class bispecific antibodies, multi-specific antibodies ...

EpiBiologics, a leader in tissue-selective extracellular protein degradation, today presented the first preclinical data on its EpiTAC bispecific antibody degrader of c-Met, a potential first-in ...